In B-cell acute lymphoblastic leukemia (B-ALL), CD19-targeted CAR-T cell therapy selects for tumor cells expressing CD19 splice variants lacking critical epitopes. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.